IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dynavax Technologies Corp. &...
November 22 2016 - 12:14PM
Business Wire
Khang & Khang LLP (the “Firm”) announces a class action
lawsuit against Dynavax Technologies Corporation (“Dynavax” or the
“Company”) (Nasdaq: DVAX). Investors who purchased or otherwise
acquired shares between March 10, 2014 and November 11, 2016
inclusive (the “Class Period”), are encouraged to contact the Firm
by the January 17, 2017 lead plaintiff motion deadline.
If you purchased shares of Dynavax during the Class Period,
please contact Joon M. Khang, Esquire, of Khang & Khang LLP,
18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone:
(949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
The complaint alleges that Dynavax made false and/or misleading
statements and/or failed to disclose: that the phase 3 HBV-23 trial
for the Company’s lead vaccine product HEPLISAV-B was not designed
in accordance with the U.S. Food and Drug Administration’s concerns
and issues; that the Company failed to provide sufficient
information to the FDA in its Revised Biologics License Application
for the drug; that Dynavax’s resources will not be sufficient for
the Company to advance the HEPLISAV-B program on its own; and that
as a result of the above, the Company’s financial statements and
statements about its business, operations, and prospects were false
and misleading and/or lacked a reasonable basis. On November 14,
2016, Dynavax announced that it received a Complete Response Letter
from the U.S. Food and Drug Administration requesting additional
information on the Company’s HEPLISAV-B product in connection with
its Biologics License Application. When this information was
disclosed, shares of Dynavax declined in value, causing investors
harm.
If you wish to learn more about this lawsuit at no
charge to you, or if you have any questions regarding this notice
or your rights, please contact Joon M. Khang, a prominent litigator
for almost two decades, by telephone: (949) 419-3834, or by e-mail
at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161122005870/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024